Given how many individuals worry about preserving lean mass, this article seemed worth sharing.
Phase 3a REDEFINE findings were unveiled at a conference in Turkey earlier this month, indicating a 12% rise in the lean mass proportion for the cagrisema arm. Naturally, absolute lean mass went down, but because fat mass was reduced to a greater extent, the lean mass percentage climbed proportionally.
For anyone thinking about including one of the amylin analogues in their approach, these outcomes look favorable.
ECO 2026: REDEFINE-1 demonstrates CagriSema's improvement in body composition - Pharmaceutical Technology
Results from the REDEFINE-1 trial (NCT05567796) were presented in Türkiye not long ago, evaluating Novo Nordisk's CagriSema in adults with obesity.
www.pharmaceutical-technology.com
Phase 3a REDEFINE findings were unveiled at a conference in Turkey earlier this month, indicating a 12% rise in the lean mass proportion for the cagrisema arm. Naturally, absolute lean mass went down, but because fat mass was reduced to a greater extent, the lean mass percentage climbed proportionally.
For anyone thinking about including one of the amylin analogues in their approach, these outcomes look favorable.
ECO 2026: REDEFINE-1 demonstrates CagriSema's improvement in body composition - Pharmaceutical Technology
Results from the REDEFINE-1 trial (NCT05567796) were presented in Türkiye not long ago, evaluating Novo Nordisk's CagriSema in adults with obesity.
www.pharmaceutical-technology.com